Intelligence Β· Patent portfolio
Vertex Pharmaceuticals (Australia) Patents
Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) β grant dates, expiration, and drug cross-links.
- Patents
- 991
- Expiring β€24m
- 63
Quick answer
Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months β use filters for patent-cliff planning.
-
US 8329662
Prodrug of an ICE inhibitor
granted -
US 8329702
Heterocycles useful as modulators of ion channels
granted -
US 8324207
Modulators of ATP-binding cassette transporters
granted -
US 8324220
Pyrimidines useful as modulators of voltage-gated ion channels
granted -
US 8324242
Modulators of ATP-binding cassette transporters
granted -
US 8318467
Inhibitors of GSK-3 and crystal structures of GSK-3Ξ² protein and protein complexes
granted -
US 8318733
Modulators of ATP-binding cassette transporters
granted -
US 8314141
Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
granted -
US 8314239
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8314125
Bicyclic derivatives as modulators of ion channels
granted -
US 8314256
Modulators of ATP-binding cassette transporters
granted -
US 8309587
Piperidine and piperazine phenyl sulphonamides as modulators of ion channels
granted -
US 8309543
Compositions useful as inhibitors of voltage-gated sodium channels
granted -
US 8304414
Pyrazole compounds useful as protein kinase inhibitors
granted -
US 8304423
Modulators of muscarinic receptors
granted -
US 8299099
Heteroaryl derivatives as CFTR modulators
granted -
US 8293929
Processes and intermediates
granted -
US 8288537
Caspase inhibitors and uses thereof
granted -
US 8288400
Compositions useful as inhibitors of protein kinases
granted -
US 8278297
Protein kinase inhibitors
granted -
US 8278306
C-met protein kinase inhibitors
granted -
US 8273896
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides
granted -
US 8268999
Tri-cyclic pyrazolopyridine kinase inhibitors
granted -
US 8268873
Inhibitors of IMPDH enzyme
granted -
US 8268829
Substituted pyrimidines useful as protein kinase inhibitors
granted -
US 8268818
Inhibitors of C-MET and uses thereof
granted -
US 8268811
Thiazoles and pyrazoles useful as kinase inhibitors
granted -
US 8269014
Thiophene analogues for the treatment or prevention of flavivirus infections
granted -
US 8269013
Substituted pyrazole inhibitors of c-Met protein kinase
granted -
US 8269026
Lupane derivatives useful for treating HIV
granted -
US 8269012
Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase
granted -
US 8263632
Aminopyridine derivatives having Aurora A selective inhibitory action
granted -
US 8263605
Modulators of muscarinic receptors
granted -
US 8263776
Inhibitors of c-Met protein kinase
granted -
US 8263777
Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase
granted -
US 8258116
Combination therapy for the treatment of HCV infection
granted -
US 8258148
Spiroindoline modulators of muscarinic receptors
granted -
US 8252787
Protein kinase inhibitors
granted -
US 8252923
Peptidomimetic protease inhibitors
granted -
US 8252541
Sodium channel protein type III Ξ±-subunit splice variant
granted -
US 8247421
5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
granted -
US 8247532
Deuterated hepatitis C protease inhibitors
granted -
US 8242272
Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof
granted -
US 8242149
Modulators of ATP-binding cassette transporters
granted -
US 8236832
Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
granted -
US 8236815
Ion channel modulators and methods of uses
granted -
US 8236833
Biphenyl derivatives as modulators of voltage gated ion channels
granted -
US 8236829
Bicyclic derivatives as modulators of voltage gated ION channels
granted
Frequently asked questions
How many patents does Vertex Pharmaceuticals (Australia) have?
991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vertex Pharmaceuticals (Australia) patents expire?
63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory